← Oncology Approval Tracker

FDA DECISION ·

Bizengri

zenocutuzumab-zbco · Merus

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced, unresectable or metastatic NRG1 fusion-positive non-small cell lung cancer or pancreatic adenocarcinoma that progressed on or after systemic therapy.

LAMPGEN ANALYSIS

Why it matters

The same HER2/HER3 bispecific targets a rare fusion in two tumor types; the label does not extend to every NRG1 fusion-positive cancer.

What research teams should watch

Coordinate fusion-capable molecular testing and specimen transfer so results are available when patients need another treatment.

PRIMARY RECORDS

Sources